Skip to main content

Table 2 Number and type of trials broken into groups according to cancer type.

From: Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review

Trial Type    Cancer Type    
  Colorectal NSCLCa Head-Neck HB-Panc Breast-Ov-Skin TOTAL
Phase I/II 20 9* 10* 5 3 47
Phase III 2 1 1 0 0 4
Case Series/Review 1 0 1 0 1 3
TOTAL 23 10 12 5 4 53
First-Line 5 2 0 0 2 9
Refractory Disease 18 8* 12* 5 2 44
  1. (NSCLCa - nonsmall cell lung cancer, HB-Panc - hepatobiliary or pancreatic, Breast-Ov-Skin - Breast or Ovarian or Cutaneous). * One study contained patients with either Head-Neck or Non-small cell lung cancer and is displayed in both groups.